Loading…
Loading…
At first glance, SPDR S&P Biotech ETF (NYSEARCA:XBI) and Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) look like two flavors of the same bet on drug discovery.
The biotechnology sector has broken out of its multiyear bear market. As macroeconomic headwinds moderate and regulatory environments stabilize, biotech ETFs are surging.
Making its debut on 06/23/2005, smart beta exchange traded fund Invesco Biotechnology & Genome ETF (PBE) provides investors broad exposure to the Health Care ETFs category of the market.
Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the Invesco Biotechnology & Genome ETF (PBE), a passively managed exchange traded fund launched on June 23, 2005.
Designed to provide broad exposure to the Health Care ETFs category of the market, the Invesco Biotechnology & Genome ETF (PBE) is a smart beta exchange traded fund launched on 06/23/2005.
The Invesco Biotechnology & Genome ETF (PBE) was launched on June 23, 2005, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of the equity market.
The Invesco Biotechnology & Genome ETF (PBE) was launched on 06/23/2005, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market.
The Invesco Biotechnology & Genome ETF (PBE) was launched on June 23, 2005, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of the equity market.
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for PBE and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.